TITLE:
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

CONDITION:
Hepatitis C, Chronic

INTERVENTION:
ribavirin [Copegus]

SUMMARY:

      The effects of treatment with different doses of PEGASYS in combination with different doses
      of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer,
      body weight greater than 85kg (187lbs) and no prior treatment with interferon. The
      anticipated time on study treatment is 3-12 months and the target sample size is 100-500
      individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  body weight >85kg (187lbs);

          -  CHC (genotype 1);

          -  liver biopsy (in <24 calendar months of first dose), with results consistent with CHC
             infection;

          -  use of 2 forms of contraception during study and 6 months after the study in both men
             and women.

        Exclusion Criteria:

          -  women who are pregnant or breastfeeding;

          -  male partners of women who are pregnant;

          -  conditions associated with decompensated liver disease;

          -  other forms of liver disease, including liver cancer;

          -  human immunodeficiency virus infection;

          -  previous treatment with an interferon, ribavirin, viramidine, levovirin or
             amantadine.
      
